Dechra Pharmaceuticals (LSE:DPH) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

DPH Aktienübersicht

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.

Über das Unternehmen

DPH fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 65.45% pro Jahr

Risikoanalyse

Zinszahlungen sind nicht ausreichend durch Erträge gedeckt

Dechra Pharmaceuticals PLC Wettbewerber

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

Indivior

LSE:INDV

UK£1.8b

HUTCHMED (China)

AIM:HCM

UK£2.6b

GSK

LSE:GSK

UK£72.5b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Dechra Pharmaceuticals
Historical stock prices
Current Share Price	UK£38.66
52 Week High	UK£41.46
52 Week Low	UK£24.73
Beta	0.78
1 Month Change	0.68%
3 Month Change	1.84%
1 Year Change	32.40%
3 Year Change	5.57%
5 Year Change	60.15%
Change since IPO	2,828.79%

Aktuelle Nachrichten und Updates

Recent updates

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Sep 08

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Aug 18

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Aug 02

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Jun 10

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

May 08

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Apr 22

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

Feb 23

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 29

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Jan 11

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Dec 04

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

Oct 15

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Sep 25

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

Sep 11

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Sep 08

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?

Jun 17

Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?

Apr 09

Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet

Mar 05

Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17

Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Feb 02

Did You Participate In Any Of Dechra Pharmaceuticals' (LON:DPH) Fantastic 268% Return ?

Jan 18

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Jan 03

Aktionärsrenditen

	DPH	GB Pharmaceuticals	GB Markt
7D	0.2%	1.2%	-1.0%
1Y	32.4%	11.8%	8.0%

Rendite im Vergleich zur Industrie: DPH übertraf die Branche UK Pharmaceuticals , die im vergangenen Jahr eine Rendite von -7.1 erzielte.

Rendite vs. Markt: DPH übertraf den Markt UK, der im vergangenen Jahr eine Rendite von -2.5 erzielte.

Preisvolatilität

Is DPH's price volatile compared to industry and market?
DPH volatility
DPH Average Weekly Movement	0.5%
Pharmaceuticals Industry Average Movement	7.8%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	2.7%

Stabiler Aktienkurs: DPH hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: DPHDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 6% auf 1% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1997	2,457	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Dechra Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
DPH grundlegende Statistiken
Marktanteil	UK£4.40b
Gewinn(TTM)	-UK£27.90m
Umsatz(TTM)	UK£761.50m

5.8x

Kurs-Umsatz-Verhältnis

-157.8x

Kurs-Gewinn-Verhältnis

Ist DPH zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
DPH Gewinn- und Verlustrechnung (TTM)
Einnahmen	UK£761.50m
Kosten der Einnahmen	UK£331.90m
Bruttogewinn	UK£429.60m
Sonstige Ausgaben	UK£457.50m
Umsatz	-UK£27.90m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.24
Bruttomarge	56.42%
Nettogewinnspanne	-3.66%
Schulden/Eigenkapital-Verhältnis	64.6%

Wie hat sich DPH auf lange Sicht entwickelt?

Historische Performance und Vergleiche

DPH Aktienübersicht

Belohnungen

Risikoanalyse

Dechra Pharmaceuticals PLC Wettbewerber

LSE:HIK

UK£4.3b

LSE:INDV

UK£1.8b

AIM:HCM

UK£2.6b

LSE:GSK

UK£72.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Recent updates

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Consensus EPS estimates fall by 10%

We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125

Upcoming dividend of UK£0.13 per share at 1.6% yield

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Full year 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Dechra Pharmaceuticals PLC Announces Executive Changes

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Less than half of directors are independent

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Non-Executive Chairman recently bought UK£99k worth of stock

Consensus EPS estimates increase by 17%

Upcoming dividend of UK£0.12 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

First half 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

CFO & Executive Director exercised options and sold UK£102k worth of stock

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Erträge & Einnahmen